

Figures 3A, 3B and 3C: The nucleotide sequence of *apex-2*. A portion of the nucleotide sequence of *apex-2*, beginning at thymine (t) at nucleotide 50 and ending at thymine (t) at nucleotide 1565 of Figure 2 is shown in SEQ ID NO: 2.

Cloud

Figures 4A, 4B and 4C: The nucleotide sequence of *apex-3* (SEQ ID NO: 3)."

REMARKS

The present Supplemental Response is in response to the Notice of Draftsperson's Drawing Review (PTO Form 948) dated April 5, 2002. Applicants enclose herewith a new set of formal drawings with corrections to FIGS. 1, 2A-2B, 3A-3C and 4A-4C. (21 sheets total). The present Supplemental Response also amends the specification to reflect these corrections to the formal drawings. Also submitted herewith is a signed copy of the Declaration of Prior Invention under 37 CFR 1.131 which was submitted unsigned with Applicants' Reply mailed December 4, 2002.

Attached hereto is "Appendix A", entitled "AMENDED SECTIONS OF SPECIFICATION WITH MARKINGS TO SHOW CHANGES MADE."

Please direct any questions concerning this Response or any aspect of this case to the undersigned attorney.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3218


Keith R. Lange
Attorney for Applicants
Reg. No. 44,201

Date: January 14, 2003

Appendix A

AMENDED SECTIONS OF SPECIFICATION WITH MARKINGS TO SHOW CHANGES MADE

Replacement paragraph for page 5, lines 9-15:

"Figures 2A and 2B: The nucleotide sequence of *apex-1* (SEQ ID NO: 1).

Figures 3A, 3B and 3C: The nucleotide sequence of *apex-2*. A portion of the nucleotide sequence of *apex-2*, beginning at thymine (t) at nucleotide 50 and ending at thymine (t) at nucleotide 1565 of Figure 2 is shown in SEQ ID NO: 2.

Figures 4A, 4B and 4C: The nucleotide sequence of *apex-3* (SEQ ID NO: 3)."